Integra LifeSciences (IART)

• Market cap: $1.68B
• 1 day: 0.41%
• 5 days: -8.52%
• 1 month: -4.93%
• 3 months: 25.29%
• 6 months: -24.52%
• Year to date: -49.60%
• 1 year: -49.47%
• 5 years: -62.80%
• 10 years: -18.41%
• Sector: Healthcare
• Industry: Surgical & Medical Instruments & Apparatus

About: Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

Employees: 3,946

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

2,645% more call options, than puts

Call options by funds: $10.6M | Put options by funds: $387K

6% less funds holding

Funds holding: 237 [Q2] → 222 (-15) [Q3]

7.48% less ownership

Funds ownership: 98.12% [Q2] → 90.64% (-7.48%) [Q3]

23% less first-time investments, than exits

New positions opened: 51 | Existing positions closed: 66

24% less repeat investments, than reductions

Existing positions increased: 62 | Existing positions reduced: 82

45% less capital invested

Capital invested by funds: $2.25B [Q2] → $1.24B (-$1.01B) [Q3]

100% less funds holding in top 10

Funds holding in top 10: 1 [Q2] → 0 (-1) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $18 17% downside
• Avg. target: $20 7% downside
• High target: $22 1% upside

3 analyst ratings

• positive: 0 0%
• neutral: 1 33%
• negative: 2 67%

Citigroup Joanne Wuensch 55% 1-year accuracy 26 / 47 met price target	1% upside $22	Sell Maintained	5 Nov 2024
Truist Securities Richard Newitter 80% 1-year accuracy 40 / 50 met price target	4% downside $21	Hold Maintained	14 Oct 2024
B of A Securities Craig Bijou 57% 1-year accuracy 4 / 7 met price target	17% downside $18	Underperform Maintained	7 Oct 2024